European Lung Cancer Congress 2026 (ELCC 2026)
Copenhagen, Denmark 25 March 2026 - 28 March 2026
Gotistobart a chemo-free option for metastatic sqNSCLC
Gotistobart monotherapy elicits an improved and durable antitumour response with a meaningful survival benefit relative to docetaxel in patients with metastatic squamous nonsmall cell lung cancer (sqNSCLC) who experience disease progression on or after anti-PD-(L)1 treatment, as shown by the results of the stage 1 PRESERVE-003 phase III trial.
Glucose level affects immunotherapy efficacy in NSCLC
A study from Israel presented at ELCC 2026 supports the role of glucose control as a modifiable host factor that could improve the effectiveness of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC).
One-time screening in never-smokers a game-changer in lung cancer
Data from a large, prospective, non-randomized study in China show that one-time low-dose computed tomography (LDCT) screening is associated with a significant reduction in lung cancer mortality in a non–risk-based population, including those who have never smoked.